Arizona is currently home to 1697 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Phoenix, Tucson, Scottsdale and Mesa. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
The Effects of Acute and Chronic Exercise on Immune Phenotype of Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Patients
NCT05876923
Recruiting
This clinical trial studies the effect of short-term (acute) and long-term (chronic) exercise on immune characteristics and function (phenotype) of patients with indolent non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Most newly-diagnosed CLL patients have early-stage disease at the time of diagnosis and do not require treatment. Despite not needing therapy, these patients have significant immune dysfunction. This may lead to an increased risk of serious infections requiring... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
06/04/2025
Locations: Mayo Clinic in Arizona, Scottsdale, Arizona
Conditions: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent Non-hodgkin Lymphoma
Register for Updates
A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma
NCT05757102
Recruiting
The primary purpose of this study is to evaluate the effects of Fluticasone Furoate (FF)/ Umeclidinium (UMEC)/ Vilanterol (VI) on lung function compared with FF/VI after 24 weeks of treatment.
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
06/04/2025
Locations: GSK Investigational Site, Paradise Valley, Arizona
Conditions: Asthma
Register for Updates
Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets
NCT05317858
Recruiting
The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier opening with Exablate Model 4000 Type 2.0/2.1 for the treatment of NSCLC brain metastases in patients who are undergoing planned FDA approved, on-label systemic therapy utilizing immune checkpoint inhibitors.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
06/04/2025
Locations: St. Joseph's Hospital and Medical Center, Phoenix, Arizona
Conditions: Brain Tumor, Non Small Cell Lung Cancer
Register for Updates
Comparison of Proton or Intensity Modulated Radiation Therapy After Surgery for Endometrial or Cervical Cancer
NCT04567771
Recruiting
This early phase I trial compares the side effects between patients treated with proton radiation therapy versus intensity modulated radiation therapy after surgery for the treatment of endometrial or cervical cancer. Radiation therapy uses high energy protons or x-rays to kill tumor cells and shrink tumors. Using quality of life questionnaires and adverse event assessments may help doctors learn whether proton radiation therapy is associated with lower acute gastrointestinal toxicities at the e... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/04/2025
Locations: Mayo Clinic in Arizona, Scottsdale, Arizona
Conditions: Cervical Carcinoma, Endometrial Carcinoma, Endometriosis, Pelvic Inflammatory Disease
Register for Updates
A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired Hepatic Function
NCT04398680
Recruiting
The purpose of this study is to assess the pharmacokinetics (PK), safety, and tolerability of belantamab mafodotin monotherapy in Relapsed/Refractory Multiple Myeloma (RRMM) participants with impaired hepatic function and in matched RRMM participants with normal hepatic function.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/04/2025
Locations: GSK Investigational Site, Tucson, Arizona
Conditions: Multiple Myeloma
Register for Updates
Clinical Evaluation of the AccuCinch® Ventricular Restoration System in Patients Who Present With Symptomatic Heart Failure With Reduced Ejection Fraction (HFrEF): The CORCINCH-HF Study
NCT04331769
Recruiting
Prospective, randomized, open-label, international, multi-center clinical study to evaluate the safety and efficacy of the AccuCinch Ventricular Restoration System in patients with heart failure and reduced ejection fraction (HFrEF).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/04/2025
Locations: Dignity Health St. Joseph's Hospital and Medical Center, Phoenix, Arizona
Conditions: Heart Failure With Reduced Ejection Fraction (HFrEF), Dilated Cardiomyopathy
Register for Updates
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)
NCT03897881
Recruiting
The purpose of this study is to assess whether postoperative adjuvant therapy with mRNA-4157 and pembrolizumab improves recurrence free survival (RFS) compared to pembrolizumab alone in participants with complete resection of cutaneous melanoma and a high risk of recurrence.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/04/2025
Locations: University of Arizona, Tucson, Arizona
Conditions: Melanoma
Register for Updates
Long COVID Cutaneous Signatures: An ARPA Funded Research Project
NCT07005947
Recruiting
This is a prospective, longitudinal study involving 300 participants for a single visit to compare Long COVID neurocutaneous biosignatures with those of other disorders affecting the sensory and autonomic nervous system.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
06/03/2025
Locations: CND Life Sciences, Scottsdale, Arizona
Conditions: Long COVID, Acute COVID-19, Postural Orthostatic Tachycardia Syndrome (POTS), Diabetic Neuropathy
Register for Updates
Study of IBI3020 Treatment in Participants With Late-Stage Solid Tumors
NCT06963281
Recruiting
The main purpose of this study is to evaluate the safety and tolerability of IBI3020 and to determine the maximum tolerated dose (MTD) and/or the recommended dose for expansion (RP2D) of IBI3020.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/03/2025
Locations: Mayo Clinic - Arizona, Pheonix, Arizona
Conditions: Solid Tumors
Register for Updates
A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection
NCT06672055
Recruiting
The primary objective of the study is to determine the relative efficacy of the investigational oral severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) vaccine tablet VXA-CoV2-3.3 compared to a currently recommended vaccine for the prevention of symptomatic Coronavirus Disease 2019 (COVID-19). In order to represent a more recently circulating SARS-CoV-2 variant, the main study endpoints will now evaluate the VXA-CoV2-3.3 (KP.2 strain) vaccine, and not the VXA-CoV2-3.1 (XBB.1.5 strain)... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2025
Locations: Avacare - Lenzmeier Family Medicine, Glendale, Arizona
Conditions: SARS-CoV2, COVID-19
Register for Updates
Time Restricted Eating in Alzheimer's Disease
NCT06429124
Recruiting
This pilot and feasibility study will enable the research team to determine the feasibility of implementing a time-restricted eating regimen among adults with mild cognitive impairment (MCI) and the impact of time-restricted eating on cognitive performance and biomarkers of metabolic health in this population. Study staff will execute the specific aims using a pre-post, non-randomized study design in which all participants receive the intervention. The intervention is a 16/8 time-restricted eati... Read More
Gender:
ALL
Ages:
Between 55 years and 89 years
Trial Updated:
06/03/2025
Locations: Arizona State University, College of Health Solutions, Phoenix, Arizona
Conditions: Mild Cognitive Impairment (MCI)
Register for Updates
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, or 7+3 in Patients With AML
NCT05735184
Recruiting
This Phase 1 study will assess the safety, tolerability, and preliminary antileukemic activity of ziftomenib in combination with venetoclax and azacitidine (ven/aza), ven, and 7+3 for two different molecularly-defined arms, NPM1-m and KMT2A-r.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2025
Locations: Mayo Clinic - Phoenix, Phoenix, Arizona
Conditions: Acute Myeloid Leukemia, Mixed Lineage Acute Leukemia, Mixed Lineage Leukemia Gene Mutation, Mixed Phenotype Acute Leukemia, Refractory AML, AML With Mutated NPM1, Acute Myeloid Leukemia Recurrent, Acute Myeloid Leukemia, in Relapse, NPM1 Mutation, KMT2Ar, Myeloid Sarcoma
Register for Updates